Recommendation of the President – Fruzaqla (fruquintinib)
On 23 April 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 49/2025 on the appraisal of drug Fruzaqla (fruquintinib) under the drug program “Treatment of patients with colorectal cancer (ICD-10: C18–C20)”